skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
ASGCT/Pharma Intelligence Quarterly Report: Q3 2021

We’re excited to share our latest report on gene, cell, and RNA therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q3 report calls out important updates and changes within the gene, cell, and RNA therapy landscape. 


Highlights of the report include:


  • Start-up financing was down from Q2, but up from a year ago
  • Approval of two new gene therapies
    • Skysona was approved for adrenoleukodystrophy in the European Union
    • Relma-cel was approved for diffuse large B-cell lymphoma in China
  • Most gene, cell, and RNA therapies in development for rare diseases are for non-oncology indications
    • Amyotrophic lateral sclerosis is in the top five for all three categories of therapy
    • Many gene therapies in development are for neurological or blood disorders
    • 323 gene therapies are in Preclinical Development; 127 gene therapies are in Phase I through Pre-Registration


Download Now

 ASGCT/Pharma Intelligence Quarterly Report: Q3 2021

Read also


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: